ClinicalTrials.gg
CompletedNCT00807963Updated Aug 15, 2018

Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone

A Phase 1 interventional study of rHuPH20 and zoledronic acid in Risk Factors for or a Diagnosis of Osteoporosis, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-08-15.

Sponsored by Halozyme Therapeutics · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 481 studies in Osteoporosis with a site in United States — 26 open to participants now, 36 under way, none of them phase 3. Osteoporosis · United States.

Enrollment
281st of 374
31 · median 73
Started
2008
with 29 others
Phase 1
40 of 481
1 open now
Registered
225th of 481
by date

Among the 481 studies in Osteoporosis with a site in United States, this one is the 281st largest by enrollment of the 374 interventional ones that give a count, is one of 30 that started in 2008, is one of 40 in phase 1, and was the 225th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

26 of the 481 studies in Osteoporosis with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 481 studies in Osteoporosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the maximum tolerated concentration (MTC) of bisphosphonate with a fixed dose of rHuPH20 administered SC, the MTC of bisphosphonate without rHuPH20 administered SC, the optimal dose of rHuPH20 to deliver bisphosphonate SC at MTC, and to compare the PK of SC administered bisphosphonate at MTC with optimal dose rHuPH20 to bisphosphonate alone.

03

Conditions studied

  • Risk Factors for or a Diagnosis of Osteoporosis

Browse trials for

Keywords

  • Pharmacokinetics
  • rHuPH20
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female volunteers 18 to 60 years of age, inclusive.
  • Intact normal skin in the area intended for administration.
  • Adequate venous access in both upper extremities.
  • Dental examination by an appropriately trained professional within 14 days of administration demonstrating no signs, symptoms, or risk factors of osteonecrosis of the jaw (ONJ).
  • Vital signs (BP, HR, temperature, respiratory rate) within normal range or, if out of range, assessed by the Investigator as not and it is mutually agreed by both Investigator and Sponsor Medical Monitor that the subject need not be excluded from the study for this reason.
  • within normal range or if out of range, assessed by the Investigator as not clinically significant and it is mutually agreed by both Investigator and Sponsor Medical Monitor that the subject need not be excluded from the study for this reason.
  • Within 14 days prior to administration, metabolic panel (e.g., sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, , ALT, alkaline phosphatase, total , albumin, and total protein) and complete blood count within the laboratory normal reference range or, if out of range, assessed by the Investigator as not clinically significant and it is mutually agreed by both Investigator and Sponsor Medical Monitor that the subject need not be excluded from the study for this laboratory value.
  • A negative serum or urine pregnancy test (if female of ) within 14 days of study drug administration.
  • Female subjects of child-bearing potential must agree to be currently practicing effective or abstinence and agree to continue to do so for at least 30 days after duration of their time on study.
  • Decision-making capacity and willingness and ability to comply with the requirements for full completion of the trial.
  • Signed, written IRB/EC-approved .

Exclusion criteria

Exclusion Criteria:

  • Lower extremity edema.
  • Lower extremity pathology that could interfere with any protocol-specified outcome assessment (e.g., cellulitis, lymphatic disorder or prior surgery, pre-existing pain syndrome, auxiliary lymph node dissection, etc.).
  • \< 60 mL/min (Cockcroft-Gault formula).
  • Any risk factor for bisphosphonate-related renal toxicity including by not limited to known predisposition to or history of renal insufficiency or renal failure, hypertension, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and subjects receiving known nephrotoxic drugs.
  • Dehydration Grade 2 or higher based on V3.0.
  • Known parathyroid gland dysfunction or any other disease that could lower blood calcium levels.
  • Known history and/or electrocardiographic evidence of atrial fibrillation.
  • Known allergy to any hyaluronidase.
  • Bisphosphonate treatment within preceding six months.
  • Known allergy or intolerance to any bisphosphonate.
  • Pregnancy or breast-feeding woman.
  • Known cardiovascular, gastrointestinal, hepatic, neurological, psychiatric, endocrine, cancer, infection, diabetes mellitus, intercurrent illness such as influenza, or other major systemic disease that would unduly risk the subject's safety or interfere with the interpretation of results.
  • Participation in a study of any drug or device within 30 days of enrollment in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Stage 1: rHuPH20 plus ZA

    Participants will receive one of several dose/concentrations of recombinant human hyaluronidase PH20 (rHuPH20) with zoledronic acid (ZA).

    Drug: rHuPH20 · Drug: zoledronic acid

  • Experimental
    Stage 2: ZA

    Participants will receive a dose/concentration of ZA administered without rHuPH20.

    Drug: zoledronic acid

  • Experimental
    Stage 3: rHuPH20 plus ZA

    Participants will receive one of several dose/concentrations of rHuPH20 with ZA.

    Drug: rHuPH20 · Drug: zoledronic acid

  • Experimental
    Stage 4: ZA

    Participants will receive an intravenous (IV) dose of 5 milligrams (mg) ZA.

    Drug: zoledronic acid

  • Experimental
    Stage 4: ZA with rHuPH20

    Participants will receive a subcutaneous (SC) dose of ZA with rHuPH20.

    Drug: rHuPH20 · Drug: zoledronic acid

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of local tolerability of injected drug product

    Time frame: Over a 7 day period

07

Study locations

1 site
  • Healthcare Discoveries, LLC/ICON Development Solutions
    San Antonio, Texas 78209, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2008
First posted
Dec 15, 2008
Start
Dec 2008
Primary completionActual
Sep 21, 2009
CompletionActual
Sep 21, 2009
Last update
Aug 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00807963
Responsible party
Sponsor
First posted
Dec 15, 2008
Start date
Dec 2008
Primary completion
Sep 21, 2009
Completion
Sep 21, 2009
Last update
Aug 15, 2018

Study contacts

Emanuel P DeNoia, MD
principal investigator · Healthcare Discoveries, LLC/ICON

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronidase (human recombinant)

Start the discussion